Trial Profile
Phase II study of ironotecan plus capecitabine in patients with antracycline and taxane pretreated metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 29 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2007 New trial record.